Navigation Links
BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
Date:6/1/2008

CHICAGO, June 1 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced positive results from its Phase II clinical trial of OncoVEX GM-CSF, an oncolytic for the treatment of advanced metastatic melanoma, at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

Clinical Trial Details

Phase II Trial Design: The Phase II trial was conducted at seven U.S. clinical centers, including the Mary Crowley Cancer Research Center, Dallas, TX; Columbia University, New York, NY; The Hubert H. Humphrey Cancer Center, Minneapolis, MN; and the University of California San Diego, San Diego, CA. Fifty patients with inoperable Stage IIIc/IV melanoma were enrolled. Patients were given OncoVEX GM-CSF injections every two weeks for up to a year. The trial was designed to measure overall objective response, which is defined as a complete response, where disease is completely eliminated, or partial response, where there is a >30% reduction in disease burden. The target efficacy endpoint detailed in the Phase II protocol and agreed with the FDA was to achieve two objective responses or stable disease >2 months.

Phase II results: Among 43 patients currently evaluable of the 50 patients enrolled, tumors injected with OncoVEX GM-CSF routinely responded, often with local complete responses or palliative benefit. With regard to systemic overall responses required for treatment success (including tumor responses at sites distant from injected tumors), six patients showed complete clinical responses; five of which are ongoing at between four and 27 months post first injection. The sixth complete response patient presented with a new lesion 15 months after initiating therapy. A further six patients achieved a partial response, five of which are ongoing 7-13 months post first injection and two of which have no disease after surgical r
'/>"/>

SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
2. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
3. Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
4. Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
5. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
6. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
7. DATATRAK International Reports First Quarter Results for 2008
8. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
9. Neurocrine Biosciences Reports First Quarter 2008 Results
10. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
11. Cardica Reports Positive Top-Line Results and Submits 510(k) for PAS-Port(R) Proximal Anastomosis System in Cardiac Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... The new report by ... applications, techniques, end users and Geography) Global Size, ... - 2020," indicates that the global DNA diagnostics ... a CAGR of 9.8% from 2014 to 2020. ... effectiveness over alternative diagnostic techniques are factors which ...
(Date:8/28/2014)... , Aug. 28, 2014   Venaxis, Inc. ... focused on obtaining FDA clearance for and commercializing its ... test for aiding in identifying children, adolescent, and young ... low risk for appendicitis, today announced it will present ... 16 th Annual Global Investment Conference being held ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... to 2020 - Broadened Diagnostic Criteria ... Market Growth despite Patent Expirations ... ADHD Therapeutics to 2020 - ...
Breaking Medicine Technology:DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 2ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 3ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 4ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 5ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 6ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 7ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria and Growing Adult Prevalence to Drive Market Growth despite Patent Expirations 8
... Encouraging 12-Month Outcomes from, Single- Center Study Involving ... 14 OrbusNeich today announced that an,interim analysis ... show good safety and efficacy in the real-world ... Presented by Professor Robbert de Winter, M.D., Ph.D., ...
... study Study needed ... Oct. 13 Advanced Circulatory Systems, Inc.,( http://www.advancedcirculatory.com ) ... in funding from the National Institutes of,Health (NIH) to ... on,those who experience cardiac arrest outside a hospital. Whatcom ...
Cached Medicine Technology:Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Whatcom County, Washington Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2
(Date:8/28/2014)... NJ Top Docs Presents Dr. Christophe Oliveira ... Top Doc, Dr. Christophe Oliveira, has just announced ... for the department of transportation. Dr. Oliveira has ... all drug testing for commercial drivers. , Having ... disorders including disk herniations, spinal stenosis, muscle sprains/strains, ...
(Date:8/28/2014)... (BRONX, NY) Researchers from Albert Einstein College of ... a potential antibody therapy for Sudan ebolavirus (SUDV), one of ... the Zaire ebolavirus (EBOV), is now devastating West Africa. First ... (most recently in 2012) that have killed more than ... ACS Chemical Biology . , Between 30 and 90 ...
(Date:8/28/2014)... In 2012, The Ben & Catherine Ivy Foundation ... brain cancer research projects at the Translational Genomics ... officially received the final regulatory approval from University ... for the trial can begin. , In the ... Trial," TGen and its clinical partners will lead ...
(Date:8/28/2014)... a Chinese herbal medication practitioner in Melbourne for ... a team of intensive care and emergency physicians ... who prescribe complementary medications. , Writing in ... Australasian College for Emergency Medicine, emergency medicine trainees ... the Intensive Care Unit at the Royal Melbourne ...
(Date:8/28/2014)... New York, New York (PRWEB) August 28, 2014 ... continue to mount in courts around the U.S., Bernstein ... & Gynecology is touting devices like Mirena as ideal ... from The Daily Press, the authors of the study ... comes to preventing pregnancy than other methods favored by ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 2Health News:NJ Top Docs Presents Dr. Christophe Oliveira of Rehabilitation Instiute of North Jersey 3Health News:Drug shows promise against Sudan strain of Ebola in mice 2Health News:TGen receives approval for patient enrollment in brain cancer clinical trial 2Health News:Deadly remedy: Warning issued about Chinese herbal medicine 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 2Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 3Health News:Mirena IUD Lawsuit News: Bernstein Liebhard LLP Notes New Study Touting IUDs as Ideal Birth Control for Teenage Girls 4
... a booster vaccination against H5N1 avian influenza given years after ... controlling a potential future pandemic. The study is published ... Infectious Diseases, now available online. , H5N1 continues to ... of mid-June, more than 60 percent of the more than ...
... ADDitude magazine,s top scientific,advisors investigate and explain non-drug ... green time and neurofeedback -,that may relieve ADHD ... how,nutrition, exercise and supplements can help treat ADHD ... magazine, the leading,publication for families and adults living ...
... boost,disability field,s quest to tie in public funding ... 16 One of the most complex,issues in ... and fund,services equitably to people with intellectual and ... Intensity Scale (SIS),assessment tool, developed by the American ...
... days of summer are here, and,for many, the rising ... an,estimated 40 percent of children and 20 percent of ... are spending three billion,dollars a year on antihistamines, often ... say in-vitro blood tests, the,latest generation of allergy tests, ...
... to irregular patterns of light and darkness can cause ... with the 24-hour solar day, negatively affecting human health ... the relationship between circadian disruptions and human maladies. ... Institute,s Lighting Research Center (LRC) provides a new framework ...
... Amsterdam, 16 July 2008 Elsevier, a leading publisher of ... Urology , the official journal of the European Association ... 5.634. , European Urology (also ... papers, fast response and an international profile. To keep up ...
Cached Medicine News:Health News:Booster vaccination may help with possible future avian influenza pandemic 2Health News:Booster vaccination may help with possible future avian influenza pandemic 3Health News:Treating ADHD Symptoms Without Medication: Free Special Report Examines Alternative ADHD Treatments 2Health News:The Supports Intensity Scale Assessment Can be Used to Build Robust Funding Methods for Developmental Disability Services, New Research Reveals 2Health News:New approach sheds light on ways Circadian disruption affects human health 2Health News:New approach sheds light on ways Circadian disruption affects human health 3
Visualize the prostate in both transverse and longitudinal planes....
Super High Density 360 degree radial rectal transducer. High resolution in the near field and lower frequencies for deeper penetration make this transducer the optimal choice when scanning the anal c...
Multi-frequency, HST, linear transducer with a longer (60mm) footprint. Available with puncture adapter and water path. This transducer incorporates ALOKAs exclusive Hemispheric Sound Technology and ...
... high frequency (13Mhz) ... and superficial imaging. ... Hemispheric Sound Technology ... This multi-frequency transducer ...
Medicine Products: